Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Navidea Biopharmaceuticals Inc

(AMEX: NAVB)
Add to Portfolio
-0.03 (-2.80%)
as of Feb 19, 2020

Last 1.04
Change -0.03 (-2.80%)
Open 1.08
Prev. Close 1.07
Today's Range
1.01
1.10
52wk Range
0.49
4.20
Volume 178,900
Avg Volume 160,815
Sector SIC-2835 In Vitro & In Vivo Diagnostic Substances

Perfomance Comparison

Name Today 3-Month 1-Year
NAVB -2.80% +15.89% -69.05%
DJIA +0.40% +6.03% +13.35%
S&P 500 +0.47% +8.62% +21.81%

Key Statistics

Annual EPS -1.05
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 21,330
Weighted Alpha -38.89
Standard Deviation -0.47
Profit Margin N/A
Beta 0.82

Growth Rates

YTD -17.46%
1-Year -68.53%
3-Year -88.62%
5-Year -96.70%
10-Year -97.32%

Opinion

Sell Hold Buy

Recent Headlines

Navidea Biopharmaceuticals Regains Compliance with

BusinessWire via COMTEX - Fri Feb 14, 11:56AM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that following the recently-ann(full story)
NAVB: 1.04 (-0.03)

Navidea Biopharmaceuticals Announces $4.2 Million Sale

BusinessWire via COMTEX - Fri Feb 14, 07:28AM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreeme(full story)
NAVB: 1.04 (-0.03)

Navidea Biopharmaceuticals Obtains Partial Dismissal

BusinessWire via COMTEX - Mon Dec 30, 05:19PM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on December 26, 2019, the (full story)
NAVB: 1.04 (-0.03)

Navidea Biopharmaceuticals Announces $1.9 Million

BusinessWire via COMTEX - Fri Dec 06, 06:23PM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreeme(full story)
NAVB: 1.04 (-0.03)

Navidea Biopharmaceuticals to Present at the 12th

BusinessWire via COMTEX - Thu Dec 05, 03:45PM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief Exec(full story)
NAVB: 1.04 (-0.03)